2007
Cost-Benefit Analysis of Second-Generation Antipsychotics and Placebo in a Randomized Trial of the Treatment of Psychosis and Aggression in Alzheimer Disease
Rosenheck RA, Leslie DL, Sindelar JL, Miller EA, Tariot PN, Dagerman KS, Davis SM, Lebowitz BD, Rabins P, Hsiao JK, Lieberman JA, Schneider LS. Cost-Benefit Analysis of Second-Generation Antipsychotics and Placebo in a Randomized Trial of the Treatment of Psychosis and Aggression in Alzheimer Disease. JAMA Psychiatry 2007, 64: 1259-1268. PMID: 17984395, DOI: 10.1001/archpsyc.64.11.1259.Peer-Reviewed Original ResearchConceptsCost-benefit analysisSecond-generation antipsychoticsGreatest net health benefitNet benefit analysisNet health benefitWholesale priceHealth Utilities Index Mark 3Economic perspectiveAlzheimer's diseaseBenefit approachHealth care costsTotal health costsHealth costsQALYsCare costsMeasures of effectivenessPlacebo-controlled trialLower health care costsHealth service useTotal health careMeasures of functionCostTreatment of psychosisQuality of lifeSensitivity analysis
2006
Cost-Effectiveness of Second-Generation Antipsychotics and Perphenazine in a Randomized Trial of Treatment for Chronic Schizophrenia
Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS, McEvoy J, Davis SM, Keefe RS, Swartz M, Perkins DO, Hsiao JK, Lieberman J. Cost-Effectiveness of Second-Generation Antipsychotics and Perphenazine in a Randomized Trial of Treatment for Chronic Schizophrenia. American Journal Of Psychiatry 2006, 163: 2080-2089. PMID: 17151158, DOI: 10.1176/ajp.2006.163.12.2080.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntipsychotic AgentsChronic DiseaseCost-Benefit AnalysisDrug CostsFollow-Up StudiesHealth Care CostsHumansLongitudinal StudiesMiddle AgedPatient DropoutsPerphenazinePsychiatric Status Rating ScalesQuality-Adjusted Life YearsResearch DesignSchizophreniaSchizophrenic PsychologyTreatment OutcomeSpecial Section on CATIE Baseline Data: Baseline Use of Concomitant Psychotropic Medications to Treat Schizophrenia in the CATIE Trial
Chakos M, Glick I, Miller A, Hamner M, Miller D, Patel J, Tapp A, Keefe R, Rosenheck R. Special Section on CATIE Baseline Data: Baseline Use of Concomitant Psychotropic Medications to Treat Schizophrenia in the CATIE Trial. Psychiatric Services 2006, 57: 1094-1101. PMID: 16870959, DOI: 10.1176/ps.2006.57.8.1094.Peer-Reviewed Original ResearchConceptsConcomitant psychotropic medicationsPsychotropic medicationsConcomitant medication useIntervention Effectiveness (CATIE) trialOnly partial responseSecond-generation antipsychoticsBetter neurocognitive functioningClinical Antipsychotic TrialsPartial responseCATIE trialMedication useAnticholinergic drugsBaseline useMedication dataMood stabilizersCases symptomsConcomitant useEffectiveness trialAntipsychotic TrialsMedicationsNeurocognitive functioningSchizophreniaBaseline dataTrialsAntipsychotics
2001
Impact of Clozapine Prescription on Inpatient Resource Utilization
SERNYAK M, ROSENHECK R, DESAI R, STOLAR M, RIPPER G. Impact of Clozapine Prescription on Inpatient Resource Utilization. The Journal Of Nervous And Mental Disease 2001, 189: 766-773. PMID: 11758660, DOI: 10.1097/00005053-200111000-00006.Peer-Reviewed Original ResearchConceptsInpatient resource utilizationClozapine treatmentInpatient daysComparison groupService utilization variablesMore inpatient daysClozapine prescriptionIndex dischargeRefractory schizophreniaConventional neurolepticsTypical neurolepticsClinical variablesVA databasesInpatient hospitalizationInpatient careYear treatmentUtilization variablesClozapineTreatmentNeurolepticsPatientsSchizophreniaTime-Limited Assertive Community Treatment for Homeless Persons With Severe Mental Illness
Rosenheck RA, Dennis D. Time-Limited Assertive Community Treatment for Homeless Persons With Severe Mental Illness. JAMA Psychiatry 2001, 58: 1073-1080. PMID: 11695955, DOI: 10.1001/archpsyc.58.11.1073.Peer-Reviewed Original ResearchConceptsSevere mental illnessMental illnessService useHealth statusOutpatient health service useSubstance abuseAssertive community treatment modelHealth service useAssertive community treatmentMental health statusRandom-effects modelCommunity treatment modelHospital daysPublic support paymentsCommunity treatmentCommunity careIllnessMental healthMore daysMonthsTreatment modelHomeless personsEffects modelAnnual cohortsHomeless clientsNational Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer Disease Trial Methodology
Schneider L, Tariot P, Lyketsos C, Dagerman K, Davis K, Davis S, Hsiao J, Jeste D, Katz I, Olin J, Pollock B, Rabins P, Rosenheck R, Small G, Lebowitz B, Lieberman J. National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer Disease Trial Methodology. American Journal Of Geriatric Psychiatry 2001, 9: 346-360. PMID: 11739062, DOI: 10.1097/00019442-200111000-00004.Peer-Reviewed Original ResearchNeuroleptic Use in the Treatment of Post-Traumatic Stress Disorder
Sernyak M, Kosten T, Fontana A, Rosenheck R. Neuroleptic Use in the Treatment of Post-Traumatic Stress Disorder. Psychiatric Quarterly 2001, 72: 197-213. PMID: 11467155, DOI: 10.1023/a:1010318414199.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntipsychotic AgentsCombat DisordersHumansMaleMiddle AgedPersonality InventoryRetrospective StudiesTreatment OutcomeVeteransConceptsPost-traumatic stress disorderTreatment of PTSDNeuroleptic useOutcome studiesStress disorderSevere post-traumatic stress disorderLarge outcome studiesUse of neurolepticsNeuroleptic-treated patientsObservational outcome studyCombat-related post-traumatic stress disorderIll patientsMedication historyClinical variablesNeuroleptic prescriptionSocio-demographic characteristicsTreatment characteristicsBaseline differencesNeurolepticsPatientsSecondary analysisPTSD symptomsCombat exposureTreatmentOutpatientsThe Effect of Institutional Fiscal Stress on the Use of Atypical Antipsychotic Medications in the Treatment of Schizophrenia
LESLIE D, ROSENHECK R. The Effect of Institutional Fiscal Stress on the Use of Atypical Antipsychotic Medications in the Treatment of Schizophrenia. The Journal Of Nervous And Mental Disease 2001, 189: 377-383. PMID: 11434638, DOI: 10.1097/00005053-200106000-00005.Peer-Reviewed Original ResearchMeSH KeywordsAlzheimer DiseaseAntipsychotic AgentsBenzodiazepinesBudgetsClozapineComorbidityDepressive DisorderDrug CostsFemaleHealth Care CostsHealth FacilitiesHumansMaleMiddle AgedOlanzapinePirenzepinePractice Patterns, Physicians'Regression AnalysisRisperidoneSchizophreniaTreatment OutcomeUnited StatesUnited States Department of Veterans AffairsConceptsAtypical antipsychotic medicationsTreatment of schizophreniaAtypical antipsychoticsAntipsychotic medicationExpensive atypical antipsychotic medicationsVeterans AffairsPrescription drug recordsGeneralized estimation equationsDrug recordsPatientsReduced likelihoodAntipsychoticsMedicationsFacility characteristicsSchizophreniaAtypicalsFinal sampleTreatmentOlanzapineRisperidone
2000
The Case Management Relationship and Outcomes of Homeless Persons With Serious Mental Illness
Chinman M, Rosenheck R, Lam J. The Case Management Relationship and Outcomes of Homeless Persons With Serious Mental Illness. Psychiatric Services 2000, 51: 1142-1147. PMID: 10970917, DOI: 10.1176/appi.ps.51.9.1142.Peer-Reviewed Original ResearchConceptsSerious mental illnessCase managersClinical outcomesMental illnessHomeless personsHigh therapeutic allianceMental health servicesCase management relationshipIll homeless personsLow allianceHigher allianceGeneral life satisfactionOutcome dataCommunity careHealth servicesMultivariate analysisSignificant associationMonthsTherapeutic allianceBaselineOutcomesIllnessDaysLife satisfactionSupport programsBenzodiazepine Use in Posttraumatic Stress Disorder among Veterans with Substance Abuse
KOSTEN T, FONTANA A, SERNYAK M, ROSENHECK R. Benzodiazepine Use in Posttraumatic Stress Disorder among Veterans with Substance Abuse. The Journal Of Nervous And Mental Disease 2000, 188: 454-459. PMID: 10919705, DOI: 10.1097/00005053-200007000-00010.Peer-Reviewed Original ResearchConceptsPosttraumatic stress disorderHealth care utilizationSubstance abuseCare utilizationBenzodiazepine useOutpatient health care utilizationStress disorderComorbid substance abuseSubstance abuse diagnosisBenzodiazepine treatmentBaseline differencesInpatient dischargesBenzodiazepine usersAbuse diagnosisPTSD patientsAdverse effectsSubstance abusersBenzodiazepinesOutcomesVeteransDisordersAbusePatientsWorseningDiagnosisComparing Consumer and Nonconsumer Provided Case Management Services for Homeless Persons with Serious Mental Illness
CHINMAN M, ROSENHECK R, LAM J, DAVIDSON L. Comparing Consumer and Nonconsumer Provided Case Management Services for Homeless Persons with Serious Mental Illness. The Journal Of Nervous And Mental Disease 2000, 188: 446-453. PMID: 10919704, DOI: 10.1097/00005053-200007000-00009.Peer-Reviewed Original ResearchConceptsMental health servicesCase managersHealth servicesSerious mental illnessCase management servicesCase management teamClinical outcomesMeasures of analysisAccess siteOutcome measuresMental illnessPresent study showConsumer providersOutcomes of servicesTime pointsAccess programClient outcomesHomeless personsOutcomesStaff ageCohortIllnessNonconsumersLarge sampleManagement services
1999
Comparison of Outcome between Homogeneous and Heterogeneous Treatment Environments in Combat-Related Posttraumatic Stress Disorder
JOHNSON D, LUBIN H, ROSENHECK R, FONTANA A, CHARNEY D, SOUTHWICK S. Comparison of Outcome between Homogeneous and Heterogeneous Treatment Environments in Combat-Related Posttraumatic Stress Disorder. The Journal Of Nervous And Mental Disease 1999, 187: 88-95. PMID: 10067948, DOI: 10.1097/00005053-199902000-00004.Peer-Reviewed Original ResearchMeSH KeywordsAdultAttitude to HealthChronic DiseaseCombat DisordersFollow-Up StudiesHospitalizationHumansMaleMental DisordersPatient SatisfactionProgram EvaluationPsychiatric Status Rating ScalesPsychotherapyPsychotherapy, GroupRegression AnalysisSocial EnvironmentSocial SupportTreatment OutcomeVeteransConceptsPosttraumatic stress disorderStress disorderVietnam combat veteransChronic posttraumatic stress disorderComparison of outcomesGeneral psychiatric patientsCombat veteransTreatment environmentTreatment outcomesInpatient programPsychiatric patientsVeteran populationDisordersVeteransOutcomesMonthsHeterogeneous conditionPatientsEnhancing Medication Compliance for People with Serious Mental Illness
Cramer J, Rosenheck R. Enhancing Medication Compliance for People with Serious Mental Illness. The Journal Of Nervous And Mental Disease 1999, 187: 53-55. PMID: 9952254, DOI: 10.1097/00005053-199901000-00009.Peer-Reviewed Original ResearchImpact of Clozapine on Negative Symptoms and on the Deficit Syndrome in Refractory Schizophrenia
Rosenheck R, Dunn L, Peszke M, Cramer J, Xu W, Thomas J, Charney D, Schizophrenia T. Impact of Clozapine on Negative Symptoms and on the Deficit Syndrome in Refractory Schizophrenia. American Journal Of Psychiatry 1999, 156: 88-93. PMID: 9892302, DOI: 10.1176/ajp.156.1.88.Peer-Reviewed Original ResearchConceptsRefractory schizophreniaDeficit syndromeNegative symptomsPositive symptomsClozapine's effectVeterans Administration TrialEffects of clozapineImpact of clozapineNegative clinical symptomsProminent negative symptomsClozapine treatmentHospitalized patientsConventional medicationsClinical symptomsControl subjectsAdministration trialClinical subtypesAnalysis of covariancePatientsClozapineSyndromeSymptomsNegative syndromeSchizophreniaTime pointsResidential Treatment for Dually Diagnosed Homeless Veterans: A Comparison of Program Types
Kasprow W, Rosenheck R, Frisman L, DiLella D. Residential Treatment for Dually Diagnosed Homeless Veterans: A Comparison of Program Types. American Journal On Addictions 1999, 8: 34-43. PMID: 10189513, DOI: 10.1080/105504999306063.Peer-Reviewed Original Research
1998
Predictors of differential response to clozapine and haloperidol
Rosenheck R, Lawson W, Crayton J, Cramer J, Xu W, Thomas J, Stolar M, Charney D, Schizophrenia F. Predictors of differential response to clozapine and haloperidol. Biological Psychiatry 1998, 44: 475-482. PMID: 9777179, DOI: 10.1016/s0006-3223(98)00117-6.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAntipsychotic AgentsClozapineDouble-Blind MethodDrug ResistanceFemaleHaloperidolHumansMalePsychiatric Status Rating ScalesQuality of LifeRacial GroupsSchizophreniaSchizophrenic PsychologySocial SupportTreatment OutcomeUnited StatesUnited States Department of Veterans AffairsConceptsQuality of lifeThree-month outcomeOnset of schizophreniaSeverity of symptomsGreater symptom reductionGreater improvementRefractory patientsRefractory schizophreniaClozapine treatmentHospital daysClinical predictorsExtrapyramidal symptomsHospitalized patientsClinical trialsBaseline predictorsSample patientsSide effectsSymptom reductionClozapinePatientsSymptomsHigher symptomsHigh levelsHaloperidolMultiple regression analysisParticipation and Outcome in a Residential Treatment and Work Therapy Program for Addictive Disorders: The Effects of Race
Rosenheck R, Seibyl C. Participation and Outcome in a Residential Treatment and Work Therapy Program for Addictive Disorders: The Effects of Race. American Journal Of Psychiatry 1998, 155: 1029-1034. PMID: 9699689, DOI: 10.1176/ajp.155.8.1029.Peer-Reviewed Original ResearchMeSH KeywordsAdultBlack or African AmericanCommunity Mental Health ServicesFemaleHumansMaleOccupational TherapyPatient Acceptance of Health CarePersonality InventoryPsychiatric Status Rating ScalesResidential TreatmentSubstance-Related DisordersTreatment OutcomeUnited StatesUnited States Department of Veterans AffairsVeteransWhite PeopleWorkConceptsWork therapy programTherapy programWhite veteransBlack participantsAddictive disordersLarger study groupBlack patientsAdmission characteristicsWorse outcomesProgram participationStudy groupPsychiatric problemsSevere alcoholMultivariate analysisDrug abuse problemsAlcohol useEffect of raceTherapeutic milieuAbuse problemsBlack veteransBlack subjectsOutcomesResidential treatmentVeteransSocial support networksINTERSITE VARIATION IN THE IMPACT OF INTENSIVE PSYCHIATRIC COMMUNITY CARE ON HOSPITAL USE
Rosenheck R, Neale M. INTERSITE VARIATION IN THE IMPACT OF INTENSIVE PSYCHIATRIC COMMUNITY CARE ON HOSPITAL USE. American Journal Of Orthopsychiatry 1998, 68: 191-200. PMID: 9589758, DOI: 10.1037/h0080329.Peer-Reviewed Original ResearchTREATMENT INVOLVEMENT AND OUTCOMES FOR FOUR SUBTYPES OF HOMELESS VETERANS
Humphreys K, Rosenheck R. TREATMENT INVOLVEMENT AND OUTCOMES FOR FOUR SUBTYPES OF HOMELESS VETERANS. American Journal Of Orthopsychiatry 1998, 68: 285-294. PMID: 9589766, DOI: 10.1037/h0080337.Peer-Reviewed Original Research
1997
Effectiveness of treatment elements in a residential-work therapy program for veterans with severe substance abuse
Rosenheck R, Seibyl C. Effectiveness of treatment elements in a residential-work therapy program for veterans with severe substance abuse. Psychiatric Services 1997, 48: 928-935. PMID: 9219302, DOI: 10.1176/ps.48.7.928.Peer-Reviewed Original ResearchMeSH KeywordsAdultChi-Square DistributionChronic DiseaseDiagnosis, Dual (Psychiatry)FemaleHumansJob SatisfactionLength of StayLongitudinal StudiesMaleOutcome and Process Assessment, Health CareProgram EvaluationRegression AnalysisSeverity of Illness IndexSheltered WorkshopsSocial AdjustmentSubstance-Related DisordersTreatment OutcomeUnited StatesVeteransConceptsSevere substance abuseSubstance abuseTreatment elementsTherapy programSevere substance use disordersAdmission risk factorsBaseline prognostic factorsLength of staySubstance use disordersPrognostic factorsToxicology screenFunctional statusRisk factorsIntensive treatmentOutcome measuresOutcome dataUse disordersRehabilitative approachVeterans AffairsOutcome domainsSignificant relationshipSubstance useOutcomesVeteransTreatment